Bullish indicating open at $55-$60, IPO prices at $37
Investing.com - Cantor Fitzgerald has reiterated an Overweight rating and $9.00 price target on Organogenesis Holdings (NASDAQ:ORGO) following the company’s second-quarter 2025 financial results. The target represents nearly 100% upside from the current price of $4.55, with analyst consensus maintaining a Strong Buy rating. According to InvestingPro analysis, the stock appears fairly valued at current levels.
Organogenesis reported total revenue of $100.8 million on August 7, falling short of both Cantor Fitzgerald and FactSet consensus estimates of $103.4 million. The results represent a year-over-year decline of approximately 23%.
The revenue decrease was primarily driven by a roughly 25% reduction in advanced wound care products, which fell to $92.7 million in the quarter.
Cantor Fitzgerald expects Organogenesis to experience "material revenue acceleration" in the second half of 2025, supported by the company’s rollout of higher-priced products.
The research firm also expressed optimism for fiscal year 2026, citing the proposed physician fee schedule that could allow for "meaningful upside to price" for Organogenesis, along with what it describes as a less competitive operating environment.
In other recent news, Organogenesis Holdings Inc. reported its second-quarter earnings for 2025, which revealed a mixed financial performance. The company posted an earnings per share (EPS) of -$0.10, falling short of the forecasted -$0.05. However, Organogenesis exceeded revenue expectations, reporting $149.2 million compared to the anticipated $103.4 million. Despite these results, total revenue showed a year-over-year decline of approximately 23%, primarily due to a 25% decrease in advanced wound care products, which totaled $92.7 million. In response to these developments, Cantor Fitzgerald raised its price target for Organogenesis from $7.00 to $9.00, maintaining an Overweight rating on the stock. These recent developments reflect the company’s current financial challenges and the mixed outlook from analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.